by no less than 10 letters in response, many of which contained errors of logic as pointed out by Fisher in replying to them."
Clearly there is confusion about the correct management of acute anaphylaxis. Much of the controversy is due to misinterpretation of published reports. In this review I reassess the role, route of delivery, dose, concentration, and efficacy of the various drugs used in anaphylaxis. Adrenaline, steroids, antihistamines, fluids, glucagon, aminophylline, and discharge drugs will be discussed in detail. I shall use the term "anaphylaxis" to refer to both anaphylactic reactions (IgE mediated immediate type hypersensitivity reactions) and anaphylactoid reactions (non-immunologically triggered), as the clinical expression and final mediators involved are identical. '2 Tables are included giving clear recommendations for first line, second line, and discharge treatment, and allowing rapid evaluation of the drugs involved.
Adrenaline BENEFICLAL EFFECTS
Adrenaline has a pivotal role as first line treatment for acute anaphylaxis.2' "' '1 Its beneficial effects include a adrenergic stimulation increasing peripheral vascular resistance and improving the blood pressure and coronary artery perfusion, reversing peripheral vasodilatation, and decreasing angio-oedema and urticaria. 01 Adrenergic stimulation has positive inotropic and chronotropic effects on cardiac activity, and 12 adrenergic effects include bronchodilatation. "4 1 Adrenergic receptors also increase intracellular cyclic adenosine monophosphate (cAMP) production in mast cells and basophils, which inhibits further inflammatory mediator release2 13 15 16 (table 1) .
ROUTES OF ADMINISTRATION
However, the correct dose and route of administration of adrenaline are unclear. The British nationalformulary recommends 0.5 to 1.0 mg or 0.5 to 1.0 ml of 1:1000 adrenaline intramuscularly as the standard initial adrenaline regime in anaphylaxis. '7 In America, 0.3 to 0.5 mg of 1:1000 adrenaline subcutaneously is recommended,2 18 whereas 0.5 to 0.8 mg subcutaneously is recommended in Sweden. 5 The clinical effectiveness of these dose variations is not well defined, nor is there convincing evidence for a difference between the intramuscular and subcutaneous routes.3 As vasodilatation is the main pathological change early in anaphylaxis, the subcutaneous or intramuscular absorption of adrenaline is rapid and effective. When anaphylaxis is treated early, is mild or progressing slowly, when venous access is difficult, or if the patient is unmonitored, 0.3 to 0.5 ml of 1:1000 adrenaline (0.3 to 0.5 mg) should be given intramuscularly . This has advantages in terms of safety and is usually highly effective.' The adrenaline dose may be repeated every five to 10 minutes, or longer according to the response (table 2) . subjects that the subcutaneous administration of adrenaline leads to prolonged but variable absorption related to local vasoconstrictor action. '9 This potential for variability is clearly unacceptable in the shocked or critically compromised patient. Unfortunately, the use of intravenous adrenaline in anaphylaxis is confused by an even wider variation in proposed doses, ranging from 1 jig/min20 to a 2 mg bolus." Moreover, many clinicians warn that intravenous adrenaline is too dangerous and rarely if ever justified, as it may cause greatly increased systolic and diastolic blood pressures with the risks of intracerebral bleeding, increased myocardial oxygen consumption inducing angina, myocardial ischaemia or even infarction, and cardiac arrhythmias including ventricular fibrillation. 4 8 22 (table 3) . However, these adverse outcomes usually occur when the adrenaline has been given too rapidly, inadequately diluted, or in excessive dose.2' 24 Cases cited from published reports on the apparent dangers of intravenous adrenaline fail to emphasise clearly that other causes such as hypoxia, hypotension, acidosis, or the direct action of the inflammatory mediators released during anaphylaxis may be responsible for the cardiovascular complications." 2 2 For instance, Sullivan described two patients with anaphylaxis given a bolus intravenous injection of 500 jg (5 1:00 000 adrenaline is prepared by drawing up 1 mg adrenaline (1 ml of 1:1000 adrenaline) in a 20 ml syringe, and 9 ml saline to give a total volume of 10 ml. All but 2 ml of this is discarded (leaving 200 jig of adrenaline in the syringe). Saline is again drawn up to a total volume of 20 ml, giving a final concentration of 10 jig per ml-that is, a 1:100 000 dilution.
Alternatively, an infusion of adrenaline may be prepared by putting 1 mg adrenaline in 100 ml normal saline, and running at 60-120 ml/hour using an infusion device (that is, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] jig/min). The rate may be altered or the infusion stopped according to the clinical response. Patients with persistent symptoms 
Antihistamines
The role of antihistamines in the management of acute anaphylaxis, although widespread, is controversial. Antihistamines and steroids should never be relied upon alone as first line treatmentt.' 12 35 Underlying the use of antihistamines are several paradoxes, which add to the confusion. receptor blockers in protecting against histamine related cardiorespiratory disturbances during routine anaesthesia.58 Table 7 Second line management of acute anaphylaxis (oxygen, adrenaline, andfluids are given first) Antihistamines HI receptor blocker diphenhydramine 25-50 mg IV or promethazine 12.5-25 mg IV, plus H2 receptor blocker cimetidine 300 mg IV slowly or ranitidine 50 A concern over the use of colloids, particularly polygeline (Haemaccel), is that this preparation itself is known to have caused anaphylactic reactions. Anaphylaxis has been reported rarely following the use of Haemaccel during general anaesthesia70 and epidural anaesthesia,7' although the exact mechanism is unclear. The makers claim that following modification of the manufacturing process Haemaccel is now nonantigenic and that possible anaphylactoid reactions may be minimised by pretreatment with combined Hi and H2 histamine receptor blockers72 (as confirmed by Lorenz58 ). They also advise against rapid infusion to normovolaemic individuals. In practice, although various colloids may produce anaphylactic and anaphylactoid reactions, these rarely if ever occur in already shocked patients, presumably because of the protective effects of their own sympathoadrenal response to the shock.35 ' 
Brown

Glucagon
Patients taking f blocking drugs appear to be at increased risk of anaphylaxis and have more severe reactions that prove difficult to treat.73 74 journal8' (p 96) ; such protocols should be known to clinicians and even inexperienced doctors should be familiar with them. Adrenaline, oxygen, and fluids are accepted first line treatments. Care with the route, dose, concentration, and speed of delivery of adrenaline in particular underpin its safety and efficacy. Antihistamines, steroids, glucagon, and aminophylline may be considered second line drugs, but require equal thought in their use, especially in weighing up the possible side effects with their perceived benefits. Finally, once the initial drama has settled, proactive discharge planning including allergy referral where appropriate ensures both the immediate and long term safety of the patient, and protects against further, often unheralded, attacks of anaphylaxis.
I am indebted to Carol Bicknell and Jennifer Nelson for their tireless efforts in the preparation of this paper.
